Zoetis Inc.
ZTSBusiness Overview
ticker: ZTS step: 01 generated: 2026-05-12 source: quick-research
Zoetis Inc. (ZTS) — Business Overview
Business Description
Zoetis is the world's largest pure-play animal health company, spun out of Pfizer in 2013. The company discovers, manufactures, and commercializes a comprehensive portfolio of medicines, vaccines, diagnostics, and digital health platforms for both companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep). The strategic narrative has shifted decisively toward companion animals — pets now generate ~65% of revenue — as pet-ownership rates and per-animal spending have outpaced livestock growth globally.
Revenue Model
Two species portfolios across two geographic segments (US + International):
- Companion Animal (~65% of revenue): Higher-margin, faster-growing, more recession-resilient. Anchored by dermatology (Apoquel, Cytopoint), pain (Librela, Solensia), and parasiticides (Simparica, Simparica Trio).
- Livestock (~35% of revenue): Cattle, swine, poultry, aquaculture, and sheep products. Slower growth, more commoditized, but provides global scale and emerging-markets exposure.
Revenue is generated through veterinarian-channel sales (~80% of companion animal goes through vet practices), plus direct-to-producer for livestock and limited e-pharmacy channels. Pricing has structural lift from biologic and monoclonal-antibody products commanding premium gross margins.
Products & Services
Companion Animal:
- Dermatology: Apoquel (oclacitinib — JAK inhibitor for canine pruritus), Cytopoint (lokivetmab — anti-IL-31 mAb), Itrafungol, Convenia
- Pain (monoclonal antibodies): Librela (bedinvetmab — anti-NGF mAb for canine OA pain), Solensia (frunevetmab — anti-NGF mAb for feline OA pain)
- Parasiticides: Simparica (sarolaner), Simparica Trio (sarolaner + moxidectin + pyrantel — flea/tick/heartworm), Revolution Plus, ProHeart
- Vaccines: Vanguard (canine), Felocell (feline), Versican
- Diagnostics: Vetscan (in-clinic blood analyzers), Vetscan Imagyst (AI-powered cytology)
- Digital health: Zoetis Reference Laboratories, Phovia, Vetscan OptiCell
Livestock:
- Cattle: BoviKalc, Bovi-Shield, Excede, Excenel, Synovex implants
- Swine: Suvaxyn, Lincomix, Improvest
- Poultry: Poulvac, Aviator, EuropharmaVet
- Aquaculture: Aquaflor, Aqualife, fish vaccines
Pipeline: Multiple next-generation monoclonal antibodies, long-acting parasiticides, and species-extension assets.
Customer Base & Go-to-Market
- Companion animal customers: Reached via ~80,000+ veterinary clinics globally; ~70%+ of companion-animal revenue is delivered through veterinarian-prescribed channels.
- Livestock customers: Direct sales to large cattle producers, hog and poultry integrators, dairy operations, and aquaculture operations. Long-cycle relationships with US and global agribusiness firms (Tyson, JBS, Smithfield, etc.).
- Distribution: 25 manufacturing sites globally + largest direct sales force in animal health. Smaller share via e-pharmacy / online vet channels.
- Geographic mix: ~55% US, ~45% International; emerging markets growing faster than developed.
No single customer represents material concentration; the fragmented vet-practice channel and global producer base diversify revenue risk.
Competitive Position
Zoetis is the global animal health leader with ~18% global market share — ahead of Boehringer Ingelheim Animal Health (~14%), Merck Animal Health (~13%), and Elanco (~10%). Key competitive advantages: (1) Monoclonal antibody leadership — first-mover in vet mAbs with Cytopoint (allergic skin), Librela (canine OA), and Solensia (feline OA); R&D head start measured in years, (2) Dermatology franchise (Apoquel + Cytopoint) — gold-standard for canine pruritus generating billions annually, though growth slowed in 2025 due to consumer-spending pressure and emerging competition, (3) R&D scale — >$650M annual R&D budget and deep pipeline in mAbs, parasiticides, and species-extension, (4) Vertical integration — 25 manufacturing sites and largest direct vet sales force sustain margins and customer reach, (5) Diagnostics + digital platform (Vetscan Imagyst AI cytology) creates an ecosystem moat with veterinary practices. Key challenges: emerging Apoquel competition (Galaxy / Modulis / cibinetide-class JAK inhibitors from Elanco, Boehringer), Librela neurological side-effect overhang (FDA "Dear Veterinarian" letter + label updates), consumer-spending pressure on pet care, and Elanco's accelerating innovation pipeline.
Key Facts
- Founded: 2013 (spun out of Pfizer Animal Health)
- Headquarters: Parsippany, NJ
- Employees: ~14,000
- Exchange: NYSE
- Sector / Industry: Health Care / Drug Manufacturers – Specialty & Generic
- Market Cap: ~$50B (May 2026)
- 12+ consecutive years of dividend increases since 2013 IPO
Financial Snapshot
ticker: ZTS step: 04 generated: 2026-05-12 source: quick-research
Zoetis Inc. (ZTS) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | YoY (25v24) |
|---|---|---|---|---|---|
| Revenue | $8.08B | $8.54B | $9.26B | $9.47B | +2.3% |
| Gross Margin | ~71% | ~71% | ~71% | ~71% | flat |
| Operating Margin (adj.) | ~37% | ~38% | ~39% | ~39% | flat |
| Net Income (GAAP) | $2.11B | $2.34B | $2.49B | $2.67B | +7.5% |
| EPS (diluted, GAAP) | $4.49 | $5.07 | $5.47 | $6.02 | +10.1% |
Cash Flow & Balance Sheet (FY2025)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$2.7B |
| Capex | ~$650M |
| Free Cash Flow | ~$2.0B |
| Cash & Investments | ~$2.0B |
| Total Debt | ~$6.5B |
Capital Return
- 12+ consecutive years of dividend increases since 2013 IPO
- Active share buyback program — typically $1–2B annually
- Capital priority: balanced between R&D reinvestment, dividend, buybacks
Key Ratios (approximate, May 2026)
- P/E (TTM, GAAP): ~19x | EV/EBITDA: ~14x | FCF Yield: ~4%
- Revenue Growth (TTM, organic operational): ~6% | Adj. Operating Margin: ~39%
- Stock price ~$116 — down ~30%+ from 52-week highs after Librela safety concerns + Q4 2025 weakness
Segment Mix (FY2024 — illustrative)
- Companion Animal: ~65% revenue, +14% operational growth
- Livestock: ~35% revenue, +5% operational growth
- US: ~55% revenue; International: ~45%
Top Franchises (illustrative)
- Simparica + Simparica Trio (parasiticides): $2B+ run-rate, growing 13–22%
- Apoquel + Cytopoint (dermatology): >$2B combined, but Q1 2026 -11% YoY under competition
- Librela + Solensia (pain mAbs): >$1B combined, growth tempered by safety concerns
- Vaccines: Vanguard, Felocell, Suvaxyn families
- Diagnostics: Vetscan platform expanding into AI cytology
Growth Profile
Zoetis is in a transition year. FY2025 organic operational growth slowed to mid-single-digits (vs. high-single / low-double historically) due to:
- Consumer-spending pullback on routine pet wellness (Gen Z/Millennial owners reducing vet visits in response to clinic price increases)
- Librela neurological safety signals leading to FDA "Dear Veterinarian" letter and label updates
- Emerging Apoquel competition from Elanco / Boehringer JAK alternatives
- Q1 2026 US revenue -8% to $1.09B
Underlying long-term thesis remains intact: only 1/3 of US dogs treated for parasites, only 12M of 32M itchy dogs use Zoetis dermatology products, and the renal mAb franchise targeting $3–4B TAM is in development for 2027 launch.
Forward Estimates
2026 guidance: Revenue $9.825–10.025B (+5% midpoint); GAAP diluted EPS $6.65–6.75; adjusted EPS $7.00–7.10. Below the company's historical 7–10% organic growth pattern, reflecting expected continued dermatology competition + cautious Librela ramp. Consensus 12-month price target ~$151 implies 30%+ upside. Bull-side scenarios pencil in successful Librela safety stabilization + 2027 renal mAb launch, returning growth to high-single / low-double-digits by 2027. Bear-side scenarios extend the consumer slowdown and dermatology share loss into 2027 with continued multiple compression.
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $ZTS.